Speaker(s): 

Jessica Laubach, BS, RRT-ACCS, Staff Member, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the use of systemic corticosteroids as a mainstay treatment for Asthma and/or COPD and their adverse health effects.
• Identify the use of biologics in the treatment of severe Asthma and/or COPD.
• Discuss limitations of the ABRA study and potential limitations of the use of Benralizumab as a treatment option.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Katie Ritz RRT-NPS, Katelyn Green, Mark Williams, RN, BSN, and Dr Ronald Wong, DO have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None